Elevated bio-ADM levels indicate disease severity and predict the need for extracorporeal organ assist in COVID-19 patients. Bio-ADM is a dynamic biomarker that indicates improved outcomes with low or decreasing levels.
A new diagnostic tool uses DPP3 to predict sepsis outcomes and guide early management. High DPP3 levels indicate severe sepsis and predict organ failure.
Researchers identified two distinct pathways leading to septic shock, involving bioactive Adrenomedullin (bio-ADM) and Dipeptidyl peptidase 3 (DPP3). Early diagnosis with biomarker-guided approaches shows promising results in personalized medicine for sepsis treatment. New diagnostics are available for rapid detection of these biomarkers.
The ADQI consensus statement recommends using a combination of damage and functional biomarkers to manage Acute Kidney Injury (AKI). Proenkephalin penKid is proposed as a marker for assessing AKI progression and kidney recovery, with CE-IVD marked assay available for point-of-care usage.
High DPP3 blood concentrations are linked to circulatory failure, cardiac depression, and acute kidney injury in burn patients. Decreasing DPP3 levels indicate a reduced risk of mortality.
Monitoring lactate and bio-ADM levels helps identify high-risk sepsis patients. Bio-ADM measures blood vessel leakage, which can detect fatal outcomes despite low or decreasing lactate levels.
Two studies demonstrate that penKid is the most accurate surrogate for assessing true GFR and predicting AKI in critically ill patients with severe burns. It can complement current diagnostic standard methods to provide timely diagnosis of impaired renal function.
A new study published by sphingotec demonstrates that biomarker bio-ADM identifies high-risk patients for septic shock and those requiring immediate life-saving therapeutic intervention. Elevated bio-ADM levels are associated with prolonged ICU stays, fatal outcomes, and distortions in endothelial function.
The penKid biomarker accurately predicted acute kidney injury (AKI), multiorgan failure, and mortality in unselected sepsis patients at presentation to the emergency department. Increasing penKid levels indicated worsening kidney function, enabling timely treatment decisions that improve outcomes.
A novel disease mechanism links circulating DPP3 to cardiac and renal dysfunction, with sustained high DPP3 levels associated with reduced cardiac function, impaired kidney function, and increased mortality. The DPP3 biomarker has high potential utility in diagnosing organ dysfunction and predicting outcomes in cardiogenic shock patients.
Italian researchers identified a biomarker bio-Adrenomedullin that correlates with good microcirculation and longevity in centenarians. The study found that low levels of this peptide hormone are associated with efficient blood perfusion, similar to that in younger individuals.